SCHEMBL14760658

SCHEMBL14760658

Cc1cc2cc(Nc3ccnc(Nc4cccc(OC5CCN(S(C)(=O)=O)C5)c4)n3)ccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
SYK P43405 11/20 0.45
EGFR P00533 2/20 0.44
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42
MERTK Q12866 1/20 0.42
NTRK2 Q16620 1/20 0.42
IGF1R P08069 1/20 0.40
JAK2 O60674 2/20 0.40
JAK3 P52333 2/20 0.40
TNNI3K Q59H18 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14024404 1.00 KDR (0.46) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL14024398 1.00 KDR (0.46) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL4874489 0.95 KDR (0.47) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL14548743 0.88 KDR (0.51) KDRSYKEGFRIGF1RJAK2
SCHEMBL14760634 0.88 KDR (0.56) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL14024507 0.88 KDR (0.56) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL14024508 0.88 KDR (0.56) KDRPDE4APDE4BPDE4CPDE4D
SCHEMBL14024486 0.83 KDR (0.57) KDRSYKFGFR1FLT1FLT4
SCHEMBL14024401 0.83 KDR (0.52) KDRSYKEGFRFGFR1FLT1
SCHEMBL14045699 0.82 PDE4A (0.43) KDRPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901143-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2014-12-02 US disclosed
EP-2154967-B9 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-07-23 EP disclosed
EP-2154967-B1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTPR LTD (BS) 2014-03-05 EP disclosed
US-20130065890-A1 PYRIMIDINE DERIVATIVES HUTCHISON MEDIPHARMA ENTERPRISES LIMITED 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065890-A1 PYRIMIDINE DERIVATIVES TYMS, KDR, FLT4 KDR 2/4885PDE4A 1369/4885PDE4B 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.